News & Events

Seasonal Allergies: Which Medication is Right for You?

The pollen count is sky-high. You’re sneezing, your eyes are itching, and you feel miserable. Seasonal allergies are real diseases that can interfere with work, school or recreation. Allergies can also trigger or worsen asthma and lead to other health problems such as sinus infections (sinusitis) and ear infections, particularly in children.

More Info
Sunscreen: How to Help Protect Your Skin from the Sun

FDA regulates sunscreens to ensure they meet safety and effectiveness standards. To improve the quality, safety, and effectiveness of sunscreens, FDA issued a proposed rule on February 21, 2019 that describes updated proposed requirements for sunscreens. Given the recognized public health benefits of sunscreen use, Americans should continue to use sunscreen with other sun protective measures as this important rulemaking effort moves forward.

More Info
Hepatitis B and C

Late breaking information, as well as an archival record of updates on safety and regulatory issues related to Hepatitis B and C.

More Info
New Drugs at FDA

Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. With its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat, FDA provides scientific and regulatory advice needed to bring new therapies to market...

More Info
Drug Safety and Availability

Information for consumers and health professionals on new drug warnings and other safety information, drug label changes, and shortages of medically necessary drug products....

More Info
FDA approves first therapy to treat patients with rare blood disorder

Today the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions....

More Info
Statement on the agency’s efforts to protect patients through postmarket drug safety surveillance practices

Public health and safety is the highest priority at the U.S. Food and Drug Administration. We maintain a robust practice of postmarket surveillance and risk evaluation programs to identify new adverse events that did not appear during the product development process, or to learn more about known adverse events...

More Info